share_log

RBC Capital Maintains Sector Perform on BioCryst Pharma, Raises Price Target to $9

Benzinga ·  Aug 4, 2023 10:36

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Sector Perform and raises the price target from $8 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment